Search CTL/CD8+ T-Cell Epitope Database

Found 8 matching records:

Displaying record number 187

HXB2 Location	Gag(180-188) p24(48-56) DNA(1327..1353)	Gag Epitope Map
Author Location	Gag(173-181)
Epitope	TPYDINQML	Epitope Alignment
Subtype	HIV-2
Species (MHC/HLA)	human(B*53)
Immunogen	HIV-2 infection
Country	Gambia
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	HIV-2

Notes

• HIV-2 Gag-specific responses were studied in 9 Gambian HIV-2 patients. High levels of HIV-2 Gag-specific CTL were found in all B*53+ patients.
• Two HIV-2-positive B*53+ patients reacted to this epitope, but failed to react to the HIV-1 equivalent peptide. One HIV-1-positive B*53+ patient failed to react to this HIV-2 epitope. Thus, this epitope is unlikely to provide HIV1/HIV2 cross-protection.

References

Gotch1993 F. Gotch, S. N. McAdam, and C. E. Allsopp et al. Cytotoxic T Cells in HIV-2 Seropositive Gambians. Identification of a Virus-Specific MHC-Restricted Peptide Epitope. J. Immunol., 151:3361-3369, 1993. PubMed ID: 7690804. Show all entries for this paper.

---

Displaying record number 53711

HXB2 Location	Gag(180-188) p24(48-56) DNA(1327..1353)	Gag Epitope Map
Author Location	Gag(180-188)
Epitope	TPYDINQML	Epitope Alignment
Epitope Name	TPY
Subtype	HIV-2
Species (MHC/HLA)	human(B53)
Immunogen	HIV-2 infection
Country	Gambia
Experimental methods	CD8 T-cell Elispot - IFNγ, Flow cytometric T-cell cytokine assay, Tetramer binding
Keywords	characterizing CD8+ T cells, HIV-2

Notes

• CD8 T-cell responses were evaluated and compared in HIV-1 and HIV-2 infected individuals living in the Gambia. A significantly greater magnitude and breadth of Gag-specific responses were found in HIV-1 infected individuals, possibly because of low or undetectable viral loads in HIV-2 infected individuals. This finding suggests that responses in HIV-2 infection reflect antigen load in plasma, as is the case in HIV-1 infection. No correlation was found between immune control of HIV-2 and the frequency of perforin-expressing virus-specific CD8 T-cells.
• 5/7 HIV-1-infected B53-positive subjects recognized TPQDLNMML, the HIV-1 version of this epitope. 3/3 HIV-2-infected B53-positive subjects responded to TPYDINQML, the HIV-2 version of the epitope.

References

Gillespie2005a Geraldine M. A. Gillespie, Susana Pinheiro, Mohammad Sayeid-Al-Jamee, Abraham Alabi, Steve Kaye, Sehu Sabally, Ramu Sarge-Njie, Harr Njai, Ken Joof, Assan Jaye, Hilton Whittle, Sarah Rowland-Jones, and Lucy Dorrell. CD8+ T Cell Responses to Human Immunodeficiency Viruses Type 2 (HIV-2) and Type 1 (HIV-1) Gag Proteins are Distinguishable by Magnitude and Breadth but not Cellular Phenotype. Eur. J. Immunol., 35(5):1445-1453, May 2005. PubMed ID: 15832290. Show all entries for this paper.

---

Displaying record number 55683

HXB2 Location	Gag(180-188) p24(48-56) DNA(1327..1353)	Gag Epitope Map
Author Location	Gag
Epitope	TPYDINQML	Epitope Alignment
Subtype	A, CRF02_AG
Species (MHC/HLA)	human(B53)
Immunogen	HIV-1 or HIV-2 infection, HIV-2 infection
Country	Gambia
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	subtype comparisons, variant cross-reactivity, HIV-2

Notes

• To comprehensively compare Gag-specific cellular immunity against HIV-1 versus HIV-2, 20 subjects each infected with HIV-1 or -2, and with similar CD4+ counts were tested for CTL response to Gag peptide pools. No significant difference was seen in magnitude/breadth of CTL response, immunodominance and frequency of targeted Gag peptides, and cross-recognition.
• HIV-2 epitope TPYDINQML is cross-reactive with its HIV-1 variants, TPQDLNTML and TPQDLNMML when tested as a part of longer peptides. B53 restriction of this epitope is previously published.

References

Ondondo2008 Beatrice O. Ondondo, Sarah L. Rowland-Jones, Lucy Dorrell, Kevin Peterson, Matthew Cotten, Hilton Whittle, and Assan Jaye. Comprehensive Analysis of HIV Gag-Specific IFN-gamma Response in HIV-1- and HIV-2-Infected Asymptomatic Patients from a Clinical Cohort in The Gambia. Eur. J. Immunol., 38(12):3549-3560, Dec 2008. PubMed ID: 19016530. Show all entries for this paper.

---

Displaying record number 55688

HXB2 Location	Gag(180-188) p24(48-56) DNA(1327..1353)	Gag Epitope Map
Author Location	Gag
Epitope	TPYDINQML	Epitope Alignment
Species (MHC/HLA)	human(B53)
Immunogen	HIV-1 or HIV-2 infection, HIV-2 infection
Country	Belgium, Senegal
Experimental methods	CD8 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	subtype comparisons, HIV-2

Notes

• To compare HIV-1 and HIV-2 CTL responses to Gag as far as homologous levels of response and cross-reactivity, 12 consecutive Gag OLP pools were used with cells from 17 HIV-1 and 17 HIV-2 patients in enhanced IFN-gamma ELISpot assays. Gag-specific homologous CTL responses were significantly higher in HIV-2 patients, but cross-reactivity in HIV-1-infected patients was broader and stronger.
• Cross-reactivity correlated with sequence similarity in HIV-2 patients, but not HIV-1 patients. CD4+ T-cell counts of HIV-2-infected patients correlated directly with homologous responses and inversely with cross-reactive responses; this was not true of HIV-1-infected subjects.
• The authors favor a model in which high HIV-2-specific CTL responses control its replication, containing immune evasion and thus limiting the possibility of cross-reaction to HIV-1 homologous epitopes.
• HIV-2 Gag epitope TPYDINQML is not cross-recognized with its homologous HIV-1 epitope, TPQDLNMML.

References

Jennes2008 Wim Jennes, Makhtar Camara, Tandakha Dièye, Souleymane Mboup, and Luc Kestens. Higher Homologous and Lower Cross-Reactive Gag-Specific T-Cell Responses in Human Immunodeficiency Virus Type 2 (HIV-2) Than in HIV-1 Infection. J. Virol., 82(17):8619-8628, Sep 2008. PubMed ID: 18562522. Show all entries for this paper.

---

Displaying record number 188

HXB2 Location	Gag(180-188) p24(48-56) DNA(1327..1353)	Gag Epitope Map
Author Location	Gag(173-181 HIV-2)
Epitope	TPYDINQML	Epitope Alignment
Subtype	HIV-2
Species (MHC/HLA)	human(B*5301)
Immunogen	HIV-2 infection
Experimental methods
Keywords	optimal epitope, HIV-2

Notes

• C. Brander notes this is a HIV-2 B*5301 epitope.

References

Llano2019 Anuska Llano, Samandhy Cedeño, Sandra Silva Arrieta, and Christian Brander. The 2019 Optimal HIV CTL Epitopes Update: Growing Diversity in Epitope Length and HLA restriction. 2019. Show all entries for this paper.

---

Displaying record number 59027

HXB2 Location	Gag(180-188) p24(48-56) DNA(1327..1353)	Gag Epitope Map
Author Location
Epitope	TPYDINQML	Epitope Alignment
Subtype	HIV-2
Species (MHC/HLA)	human(B*5301)
Immunogen	HIV-2 infection
Country	Guinea-Bissau
Experimental methods	CD8 T-cell Elispot - IFNγ, Intracellular cytokine staining, Tetramer binding
Keywords	HIV-2

Notes

• To study immune correlations with natural HIV-2 control, a cohort in Guinea-Bissau was studied for 2 decades. 33 controllers were significantly associated with a CTL response that was high-magnitude and polyfunctional. The CTL response was of restricted breadth as it was to a specific epitope for the most part, as opposed to similar HIV-1 associated CTL - 80% of the controllers mounted a response to only one HIV-2 epitope. There was no correlation with perforin upregulation. Gag-specific, but not Env-specific responses defined viral control.
• HLA-B*5301-restricted immunodominant HIV-2 p26 epitope, TPYDINQML, may contribute to viral control as seen by EliSpot.

References

deSilva2013 Thushan I. de Silva, Yanchun Peng, Aleksandra Leligdowicz, Irfan Zaidi, Lucy Li, Harry Griffin, Marie-Eve Blais, Tim Vincent, Mavinga Saraiva, Louis-Marie Yindom, Carla van Tienen, Philippa Easterbrook, Assan Jaye, Hilton Whittle, Tao Dong, and Sarah L. Rowland-Jones. Correlates of T-Cell-Mediated Viral Control and Phenotype of CD8+ T Cells in HIV-2, a Naturally Contained Human Retroviral Infection. Blood, 121(21):4330-4339, 23 May 2013. PubMed ID: 23558015. Show all entries for this paper.

---

Displaying record number 55522

HXB2 Location	Gag(180-188) p24(48-56) DNA(1327..1353)	Gag Epitope Map
Author Location	Gag(182-190 HIV-2 ROD)
Epitope	TPYDINQML	Epitope Alignment
Epitope Name	TPY
Subtype	HIV-2
Species (MHC/HLA)	human(B*5801)
Immunogen	HIV-2 infection
Patient MHC/HLA	A*0101, A*2402, B*07, B*5801
Country	India
Experimental methods
Keywords	escape, HIV-2

Notes

• This longitudinal case study in 1 patient found 3 amino acid substitutions - V286I in Gag and K303T, N337K/R in Env with an increase in HIV-2 load. Sites encompassing these 3 substitutions are candidates for HIV-2 epitopes.
• Epitope TPYDINQML of Gag 182-190 (relative to strain SMM239), restricted by HLA-B*5801, showed no changes in this patient.

References

Kageyama2008 Seiji Kageyama, Janak K. Maniar, Dattatray G. Saple, Kei Numazaki, Takashi Kurimura, and Hiroshi Ichimura. HIV-2 Amino Acid Substitutions in Gag and Env Proteins Occurring Simultaneously with Viral Load Upsurge in a Drug-Naïve Patient. J. Infect. Chemother., 14(2):151-155, Apr 2008. PubMed ID: 18622680. Show all entries for this paper.

---

Displaying record number 61219

HXB2 Location	Gag(180-188) p24(48-56) DNA(1327..1353)	Gag Epitope Map
Author Location	p24
Epitope	TPYDINQML	Epitope Alignment
Epitope Name	TL9
Species (MHC/HLA)	human
Immunogen	HIV-2 infection
Patient MHC/HLA	012-006: A*03, A*23, B*35, B*53, Cw*04; 012-088: A*02, B*27, B*53, Cw*02, Cw*04; 019-010: A*33, A*68, B*53, Cw*04; 023-008: A*34, B*07, B*53, Cw*04, Cw*07; 036-018: A*03, B*35, B*53, Cw*04; 045-007: A*33, B*53, Cw*04; 082-005: A*23, A*34, B*53, Cw*04
Country	France
Experimental methods	CTL suppression of replication, Intracellular cytokine staining
Keywords	HIV-2

Notes

• CTL lymphopoietic potential and virus suppressive capacity were studied in 20 cART-naive, HIV-2-positive subjects with controlled viremia (HIC2). Production of HIV-2 Gag-specific CTL with (1) early memory differentiation as well as (2) robust effector potential was preserved in HIC2.
• 7/20 subjects were B*5301-positive and all recognized immunodominant Gag p24 epitope TPYDINQML (TL9).

References

Angin2016 Mathieu Angin, Glenn Wong, Laura Papagno, Pierre Versmisse, Annie David, Charles Bayard, Bénédicte Charmeteau-De Muylder, Amel Besseghir, Rodolphe Thiébaut, Faroudy Boufassa, Gianfranco Pancino, Delphine Sauce, Olivier Lambotte, Françoise Brun-Vézinet, Sophie Matheron, Sarah L. Rowland-Jones, Rémi Cheynier, Asier Sáez-Cirión, Victor Appay, and ANRS CO5 IMMUNOVIR-2 Study Group. Preservation of Lymphopoietic Potential and Virus Suppressive Capacity by CD8+ T Cells in HIV-2-Infected Controllers. J. Immunol., 197(7):2787-2795, 1 Oct 2016. PubMed ID: 27566819. Show all entries for this paper.

---